期刊
GENES AND IMMUNITY
卷 11, 期 3, 页码 219-231出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/gene.2010.4
关键词
lymphangiogenesis; inflammation; systems genetics; colitis
资金
- National Institutes of Health [CA69184, DK44240]
- Swiss National Science Fund [3100A0-108207]
- Austrian Science Foundation [S9408-B11]
- Cancer League Zurich, Oncosuisse
- European Commission [LSHC-CT-2005-518178]
- Broad Biomedical Research Program
Inflammatory bowel disease (IBD) is a chronic debilitating disease resulting from a complex interaction of multiple genetic factors with the environment. To identify modifier genes of IBD, we used an F2 intercross of IBD-resistant C57BL/6J-II10(-/-) mice and IBD-susceptible C3H/HeJBir-II10(-/-) (C3Bir-II10(-/-)) mice. We found a prominent involvement of lymphatic vessels in IBD and applied a scoring system to quantify lymphatic vascular changes. Quantitative trait locus (QTL) analyses revealed a large-effect QTL on chromosome 3, mapping to an interval of 43.6 Mbp. This candidate interval was narrowed by fine mapping to 22 Mbp, and candidate genes were analyzed by a systems genetics approach that included quantitative gene expression profiling, search for functional polymorphisms, and haplotype block analysis. We identified vascular adhesion molecule 1 (Vcam1) as a candidate modifier gene in the interleukin 10-deficient mouse model of IBD. Importantly, VCAM1 protein levels were increased in susceptible C3H/HeJ mice, compared with C57BL/6J mice; systemic blockade of VCAM1 in C3Bir-II10(-/-) mice reduced their inflammatory lymphatic vessel changes. These results indicate that genetically determined expression differences of VCAM1 are associated with susceptibility to colon inflammation, which is accompanied by extensive lymphatic vessel changes. VCAM1 is, therefore, a promising therapeutic target for IBD. Genes and Immunity (2010) 11, 219-231; doi:10.1038/gene.2010.4; published online 11 March 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据